JAMES B. BREITMEYER - 13 Apr 2023 Form 4 Insider Report for Oncternal Therapeutics, Inc.

Role
Chief Executive Officer, Director
Signature
/s/Chase C. Leavitt, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
13 Apr 2023
Net transactions value
+$43,930
Form type
4
Filing time
17 Apr 2023, 06:00:07 UTC
Previous filing
24 Feb 2023
Next filing
05 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ONCT Common Stock Purchase $29,000 +100,000 +215% $0.2900 146,544 13 Apr 2023 By Family Trust
transaction ONCT Common Stock Purchase $14,277 +47,750 +33% $0.2990 194,294 14 Apr 2023 By Family Trust
transaction ONCT Common Stock Purchase $652 +2,250 +1.2% $0.2900 196,544 14 Apr 2023 By Family Trust
holding ONCT Common Stock 541,981 13 Apr 2023 Direct
holding ONCT Common Stock 23,918 13 Apr 2023 By Spouse
holding ONCT Common Stock 733 13 Apr 2023 By Child
* An asterisk sign (*) next to the price indicates that the price is likely invalid.